Achuthan Sourianarayanane

Dr. Achuthan Sourianarayanane

Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
ASAchuthan Sourianarayanane
Achuthan Sourianarayanane
SASowminya Arikapudi
Sowminya Arikapudi
AMArthur J. McCullough
Arthur J. McCullough
AHAbhinav Humar
Abhinav Humar
Background: Nonalcoholic steatohepatitis (NASH) is known to recur following liver transplantation (LT). Metabolic risk factors increase with immunosuppression. However, the rate of fibrosis progression following LT for NASH while on immunosuppression is less clear. Aim: The incidences of steatosis, NASH, and fibrosis following LT for NASH were quantified and compared with those transplanted for alcoholic liver disease (ALD). Patients and methods: Records of all NASH patients and 1 : 2 match with ALD transplant recipients between 2001 and 2006 were reviewed retrospectively. Patients without liver biopsies beyond 2 months following LT were excluded. Results: NASH patients (n=77) were older (P=0.0006) and less likely male (P<0.001) than ALD patients (n=108). The incidence of steatosis, NASH, and fibrosis stage increased at 1, 3, and 5 years in both groups. Although steatosis and nonalcoholic fatty liver disease activity scores were higher, fibrosis was lower in NASH compared with ALD (0.43 vs. 1.0 stage/year; P=0.0045). The incremental increase in the rate of fibrosis was faster in the first year compared with 4–5 years (0.8 vs. 0.04 stage/year) following LT. The rate of fibrosis progression during 4–5 years was decreased in NASH compared with ALD recipients (0.04 vs. 0.33 stage/year; P=0.015). NASH etiology was associated with reduced rate of fibrosis progression (odds ratio=0.67) on multivariate analysis. Conclusion: Despite having more steatosis and inflammation, progression of fibrosis was slower in NASH compared with ALD recipients. Fibrosis progression slows with time following LT on immunosuppression and approximates the pretransplant progression rate by year 5.

24 February 2015 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
GGGeorge Boon Bee Goh
George Boon Bee Goh
MPMangesh R. Pagadala
Mangesh R. Pagadala
JDJaividhya Dasarathy
Jaividhya Dasarathy
AUAynur Unalp-Arida
Aynur Unalp-Arida
RPRish K. Pai
Rish K. Pai
AMArthur J. McCullough
Arthur J. McCullough

13 July 2022 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
ASAchuthan Sourianarayanane
Achuthan Sourianarayanane
AMArthur J McCullough
Arthur J McCullough

1 April 2015 in JAMA Surgery
Verified
Journal Article
Closed access
PDF file
SASayee Sundar Alagusundaramoorthy
Sayee Sundar Alagusundaramoorthy
VVValery Vilchez
Valery Vilchez
AZAnthony Zanni
Anthony Zanni
ASAchuthan Sourianarayanane
Achuthan Sourianarayanane
EMErin Maynard
Erin Maynard
RGRoberto Gedaly
Roberto Gedaly
Research from JAMA Surgery — Role of Transplantation in the Treatment of Benign Solid Tumors of the Liver — A Review of the United Network of Organ Sharing Data Set

15 April 2023 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
ASAchuthan Sourianarayanane
Achuthan Sourianarayanane
AMArthur J McCullough
Arthur J McCullough
Background: The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing in the USA. Some of these patients develop non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis. Ultrasound imaging is one of the most used modalities for diagnosing hepatic steatosis. Primary care providers are increasingly using point-of-care ultrasound (POCUS), which could increase the number of subjects diagnosed with NAFLD. This study evaluates the accuracy of POCUS in identifying patients with NASH. Methods: Patients with hepatic steatosis without excess alcohol intake or other liver diseases undergoing liver biopsy were included in this study. These patients underwent POCUS and vibration-controlled transient elastography (VCTE) evaluations within 3 months of a liver biopsy. A comparison of POCUS data with liver histology and VCTE were made to assess the validity of POCUS evaluation in diagnosing NAFLD and NASH. Results: The steatosis score from the liver histology had a low correlation with the controlled attenuation parameter score from VCTE (r = 0.27) and a moderate correlation with the grade of steatosis detected by the POCUS exam (r = 0.57). The NAFLD activity score on histology was found to correlate with the ultrasonographic fatty liver index (USFLI) from the POCUS exam (r = 0.59). A USFLI ≥ 6 diagnosed NASH with a sensitivity of 81%, and a value of ≤3 ruled out the diagnosis of NASH with a sensitivity of 100%. Conclusion: The provider can use the POCUS exam in clinical practice to diagnose NAFLD and reliably stratify patients who have NASH.

28 July 2024 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
ASAchuthan Sourianarayanane
Achuthan Sourianarayanane
MSMichelle R. Salemi
Michelle R. Salemi
BPBrett Phinney
Brett Phinney
AMArthur J. McCullough
Arthur J. McCullough